124 results about "Alkyne formation" patented technology

A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: water and micelles comprising paclitaxel and a pharmaceutically-acceptable, water-miscible solubilizer forming the micelles, the solubilizer selected from the group consisting of solubilizers having the general structuresR1COOR2, R1CONR2, and R1COR2,wherein R1 is a hydrophobic C3-C50 alkane, alkene or alkyne and R2 is a hydrophilic moiety. The solubilizer is selected such that it does not have a pKa less than about 6.

The invention discloses a copper catalyst for selective hydrogenation of mixed C4 and a preparation method of the copper catalyst. The copper catalyst comprises an alumina carrier, 5-50% of active component (Cu), and 0.1-20% of an assistant (one or more of Ag, Co, Fe, Mn, Ni, Zn, Cr and Pd). In the preparation process of the catalyst, organic amine is added to be subjected to complexing with a metal component to effectively improve the uniformity and the dispersibility of alloy formed on the surface of the catalyst. The copper catalyst is used for the process of removing alkyne through selective hydrogenation by the mixed C4, and has good selectivity and long operation cycle.

There is provided inter alia a substrate with a surface having a hydrophilic coating comprising a cross-linked copolymer of components A and B, and optional components C and D; wherein

• • component A comprises one or more C₂-C₁₆ hydrophilic monomers each bearing one or more alkene and/or alkyne groups;
  • component B comprises one or more hydrophilic polymers each bearing two or more alkene and/or alkyne groups;
  • component C, if present, comprises one or more beneficial agents each bearing one or more alkene or alkyne groups; and
  • component D, if present, comprises one or more low molecular weight cross-linking agents each bearing two or more functional groups independently selected from thiol, alkene and alkyne groups;
  • wherein the cross-linked copolymer is formed by radical polymerisation involving the alkene and/or alkyne groups of components A, B and C (if present) and involving the functional groups of component D (if present);
  • wherein the hydrophilic coating optionally comprises component E which comprises one or more beneficial agents, wherein component E does not form a copolymer with components A, B, C (if present) and D (if present);
  • and wherein the hydrophilic coating is covalently attached to the surface of the substrate.

The invention relates to a Pd-Ag/Al2O3-TiO2 catalyst for selective hydrogenation of cracked gasoline or its fractions. The catalyst comprises an Al2O3-TiO2 composite as a carrier, and active components of Pd and Ag loaded on the carrier, wherein the Pd content accounts for 0.15-0.5wt% of the total weight of the catalyst, and the Ag content accounts for 0.8-4.5wt% of the total weight of the catalyst. Compared with same catalysts, the catalyst for the hydrogenation of the cracked gasoline or its fractions of the invention has the advantages of high hydrogenation selectivity at a low temperature, strong As impurity resistance, large charging capacity and stable activity. In addition, the invention also relates to a preparation method of the catalyst. The catalyst of the invention can also be used for the selective hydrogenation of alkynes and/or diolefins of other petroleum hydrocarbons.

High efficiency processes for producing olefins, alkynes, and hydrogen co-production from light hydrocarbons are disclosed. In one version, the method includes the steps of combusting hydrogen and oxygen in a combustion zone of a pyrolytic reactor to create a combustion gas stream, transitioning a velocity of the combustion gas stream from subsonic to supersonic in an expansion zone of the pyrolytic reactor, injecting a light hydrocarbon into the supersonic combustion gas stream to create a mixed stream including the light hydrocarbon, transitioning the velocity of the mixed stream from supersonic to subsonic in a reaction zone of the pyrolytic reactor to produce acetylene, and catalytically hydrogenating the acetylene in a hydrogenation zone to produce ethylene. In certain embodiments, the carbon efficiency is improved using methanation techniques.

The invention provides a hydrogenation catalyst preparation method and application of hydrogenation catalyst in selective hydrogenation reaction. Aluminum oxide is utilized as a carrier; the hydrogenation catalyst is prepared from boehmite; cane sugar, glucose and soluble starch are added into carrier precursor in a preparation process to serves as structural aids and are roasted in inert atmosphere and air sequentially, and roasting temperature is 450 to 1000 DEG C. Active ingredients of the catalyst are loaded by an impregnation method, and the active ingredients are chosen from alloy which is prepared from one or several of metal Ru, Pd and Pt and one or several of Cu, Ag and Au. The catalyst can be applied to olefin preparation by alkyne selective hydrogenation reaction.

A fatty acid analogue of the general formula: R₁-[x_i-CH₂]_n—COOR₂, wherein R₁ is: a C₂-C₂₄ alkene with one or more double bonds and/or with one or more triple bonds, and/or a C₂-C₂₄ alkyne, and/or a C₁-C₂₄ alkyl, or a C₁-C₂₄ alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₂-C₅ acyloxy or C₁-C₄ alkyl, and wherein R2 represents hydrogen or C₁-C₄ alkyl, and wherein n is an integer from 1 to 12, and wherein i is an odd number and indicates the position relative to COOR₂, and wherein X_i independent of each other are selected from the group comprising O, S, SO, SO₂, Se and CH₂, and with the proviso that at least one of the X_i is not CH₂, and or a salt, prodrug or complex thereof is used in the treatment and/or prevention of primary and secondary metastatic neoplasms.

The present invention relates to methods of preventing or treating a mammal with a viral-induced disorder. The method involves administering to the mammal a therapeutically effective amount of a compound represented by Formula I, as shown below:

or a pharmaceutically acceptable salt thereof, with X, R₀, R₁, and R₂ defined herein, under conditions effective to prevent or treat the viral-induced disorder.

An addition-reaction-curable silicone rubber composition comprising: 0.001 to 5 mass % of a metal deactivator and 0.001 to 5 mass % of a curing-retarder selected from an alcohol derivative having carbon-carbon triple bonds, an enzyne compound, an alkenyl-containing low-molecular-weight organosiloxane compound, or an alkyne-containing silane; and a molded body produced by curing the aforementioned addition-reaction-curable silicone rubber composition. The addition-reaction-curable silicone rubber composition is capable of producing a molded silicone rubber body, which is obtained with low compression set without resorting to secondary thermal treatment.

A process for the manufacture of a functional (per)fluoropolyether derivative comprising at least one triazole group, such process comprising: (1) reacting a (per)fluoropolyether hydroxyl derivative having at least one hydroxyl group [derivative (PFPE-OH)] with an activating agent, to yield an activated (per)fluoropolyether hydroxyl derivative comprising at least one activated hydroxyl group [derivative (a-PFPE-OH)]; (2) reacting said activated (per)fluoropolyether hydroxyl derivative [derivative (a-PFPE-OH)] with at least one azide salt to yield a functional (per)fluoropolyether derivative comprising at least one azido group [derivative (PFPE-N₃)]; and (3) reacting said functional (per)fluoropolyether derivative comprising at least one azido group [derivative (PFPE-N₃)] with a hydrocarbon compound having a terminal alkyne group to yield a functional (per)fluoropolyether derivative comprising at least one triazole group [derivative (PFPE-azole)].

The present disclosure provides fluorogenic azide compounds. Also provided are methods of using the subject compounds for labelling a target biomolecule that includes an alkyne. In some embodiments, the method includes contacting the biomolecule with a fluorogenic azide compound, wherein the contacting results in covalent linkage of the compound with the alkyne moiety of the target biomolecule.

The invention provides a loaded alloy catalyst for selective hydrogenation of alkyne and a preparation method thereof. The preparation method of the catalyst includes: dispersing metal salts containing Pd, M and Y in deionized water, using alkali as the precipitant, conducting coprecipitation reduction to obtain a bimetallic catalyst precursor, performing drying and roasting to form a PdMOx/YO2 composite oxide, and then conducting hydrogen reduction to obtain a PdM/YO2 catalyst. The active component of the catalyst is a palladium-containing alloy with a loading amount of 0.6-6wt% and a particle size of 1.5-5.5nm. The catalyst has the characteristics that: the active component is Pd-containing uniform alloy particles, and the alloy particles are stably inlaid on the carrier surface to produce metal-carrier strong interaction. The catalyst has excellent catalytic activity, selectivity and good recyclability in the reaction of olefin preparation by catalytic hydrogenation of alkyne.

A process for making an ion-conducting polymer comprises cross-linking polymers having functional groups such as alkyne groups and azide groups. An example ion-conducting polymer has cross-links including nitrogen-containing heterocycles formed by the reaction between the functional groups, such as 1,2,3-triazole groups formed by a cycloaddition reaction between alkyne and azide groups. The ion-conducting polymer may be used in an ion-electrolyte membrane. Examples include a proton-electrolyte membrane useful for fuel cells.

The present invention provides methods of treating microbacterial infections comprising administering to a subject in need thereof, a composition comprising a compound of formula I:

wherein:

• • X¹, X² and X³ are selected from the group consisting of oxygen, sulfur, aminoalkyl, alkoxy, aryl, and heteroaryl, unsubstituted or substituted; and
  • R¹, R², R³ and R⁴ are selected from the group consisting of hydrogen, actinium, silicon, germanium, cyano, alkyl, alkoxy, allyl, alkenyl, alkynyl, alkylaryl, arylalkyl, aminoalkyl, alkylamino, alkene, alkyne, aryl, halide, alkylhalide, alkyloxyalkyl, thioalkyl, alkylthioalkyl, alkylamino, cycloalkyl, heterocyclyl, unsubstituted or substituted; or a pharmaceutically acceptable salt thereof. The present invention further provides methods of treating bacterial infections comprising administering to a subject in need thereof, an effective amount of a pharmaceutical composition comprising uric acid, urate, derivatives thereof, salts and hydrates thereof and prodrugs thereof and a pharmaceutically acceptable carrier.

The invention discloses a preparation method of a novel sulfonated polyetheretherketone/sulfonated graphene oxide composite proton exchange membrane, and relates to the field of composite materials. SGO-C-triple bond-C is prepared; polyetheretherketone is dissilved in concentrated sulfuric acid to prepare sulfonated polyetheretherketone; SPEEK-CH2N3 is prepared through a chloromethylation reactionand an azidation reaction; SPEEK-SGO is prepared by a click chemical reaction of alkyne and azide under the catalysis of CuBr; and the SPEEK-SGO composite membrane is prepared by a solution casting blending phase transformation process in order to achieve the preparation and modification of the sulfonated polyetheretherketone membrane. The composite proton exchange membrane improves the proton conductivity, the coulombic efficiency and the power density of polymer membranes in fuel cells, and can be applied to the field of chemical industry.

The invention provides a selective hydrogenation catalyst for C5 fraction. The catalyst takes a compound of alumina and molecular sieves as a carrier and takes metals in the IA or IIA group, the VIII group, the IVA group and the IB group as active components. The compound carrier is soaked in aqueous solution of metallic compound in the IA/IIA group and is soaked in water soluble salt solution of the metals in the VIII group, nitrate solution of the metals in the IVA group and nitrate solution of the metals in the IB group by one step or multiple steps; after being soaked by one step, the compound carrier is dried for 12-20h at the temperature of 80-200 DEG.C, and then is calcined for 1-12 hours at the temperature of 350-650 DEG C. When the selective hydrogenation is carried out on unsaturated compounds in the C5 fraction by the catalyst, the transformation ratio of alkyne hydrogenation is more than or equal to 45%, the transformation ratio of dialkene is 15-35%, the content of alpha position olefin after hydrogenation is more than or equal to 15% and can meet the need of producing alpha-resin with high quality in the process of subsequent production, thus improving the quality of the alpha-resin products.